Show Me the Money! Process Modeling in Pharma from the Investor’s Point of View
暂无分享,去创建一个
Christos Varsakelis | Moritz von Stosch | Sandrine Dessoy | Alexander Pysik | M. Stosch | C. Varsakelis | S. Dessoy | Alexander Pysik
[1] Eric David,et al. Pharmaceutical R&D: the road to positive returns , 2009, Nature Reviews Drug Discovery.
[2] Joan M. Smith. A Business Case for Using Modeling and Simulation in Developmental Testing , 2001 .
[3] San Kiang,et al. Can pharmaceutical process development become high tech , 2006 .
[4] Hiroshi Nakagawa,et al. Decision Support Method for the Choice between Batch and Continuous Technologies in Solid Drug Product Manufacturing , 2018 .
[5] R. W. Hansen,et al. The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.
[6] Fernando J. Muzzio,et al. Pharmaceutical engineering science—New approaches to pharmaceutical development and manufacturing , 2010 .
[7] Sharmista Chatterjee,et al. An Overview of the Role of Mathematical Models in Implementation of Quality by Design Paradigm for Drug Development and Manufacture , 2017 .
[8] Gordon Grant,et al. Building a Business Case for Modeling and Simulation , 2000 .
[9] Steve Gordon,et al. Calculating Return on Investment for U.S. Department of Defense Modeling and Simulation , 2011 .
[10] Troy Shinbrot,et al. Powder technology in the pharmaceutical industry: the need to catch up fast , 2002 .
[11] Krist V. Gernaey,et al. Introducing mechanistic models in Process Analytical Technology education. , 2009, Biotechnology journal.
[12] Alexandros Koulouris,et al. The Role of Process Simulation in Pharmaceutical Process Development and Product Commercialization , 2002 .
[13] J. Strube,et al. Accelerating Biologics Manufacturing by Upstream Process Modelling , 2019, Processes.
[14] Marianthi G. Ierapetritou,et al. Dynamic Flowsheet Model Development and Sensitivity Analysis of a Continuous Pharmaceutical Tablet Manufacturing Process Using the Wet Granulation Route , 2019, Processes.
[15] Henry G. Grabowski,et al. A New Look at the Returns and Risks to Pharmaceutical R&D , 1990 .
[16] John R. Carter. A Business Case for Modeling and Simulation , 2001 .
[17] Konrad Hungerbühler,et al. Data-driven tiered procedure for enhancing yield in drug product manufacturing , 2016, Comput. Chem. Eng..
[18] T. De Beer,et al. Mechanistic modelling of infrared mediated energy transfer during the primary drying step of a continuous freeze‐drying process , 2017, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[19] Eli Feinerman,et al. Risk and Probability Premiums for CARA Utility Functions , 1993 .
[20] Kerry Back,et al. Asset Pricing and Portfolio Choice Theory , 2010 .
[21] Blake Johnson,et al. A Practical Method for Valuing Real Options: The Boeing Approach , 2007 .
[22] Salvador García-Muñoz,et al. Definition of Design Spaces Using Mechanistic Models and Geometric Projections of Probability Maps , 2015 .
[23] Hirokazu Sugiyama,et al. Uncertainty‐conscious methodology for process performance assessment in biopharmaceutical drug product manufacturing , 2018 .
[25] Marianthi G. Ierapetritou,et al. Challenges and opportunities in modeling pharmaceutical manufacturing processes , 2015, Comput. Chem. Eng..
[26] J. Rantanen,et al. The Future of Pharmaceutical Manufacturing Sciences , 2015, Journal of pharmaceutical sciences.